Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Musculoskeletal Disease, Geroscience Research Center, National Center for Geriatrics and Gerontology, Obu, Japan.
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2961-2973. doi: 10.1002/jcsm.13102. Epub 2022 Oct 13.
Vitamin D is an essential nutrient in musculoskeletal function; however, its relationship to sarcopenia remains ambiguous, and the mechanisms and targets of vitamin D activity have not been elucidated. This study aimed to clarify the role of vitamin D in mature skeletal muscle and its relationship with sarcopenia.
This epidemiological study included 1653 community residents who participated in both the fifth and seventh waves of the National Institute for Longevity Sciences, Longitudinal Study of Aging and had complete background data. Participants were classified into two groups: vitamin D-deficient (serum 25-hydroxyvitamin D < 20 ng/mL) and non-deficient (serum 25-hydroxyvitamin D ≥ 20 ng/mL); they underwent propensity-score matching for background factors (age, sex, height, weight, comorbidities, smoker, alcohol intake, energy intake, vitamin D intake, steps, activity, season and sarcopenia). Changes in muscle strength and mass over the 4-year period were compared. For basic analysis, we generated Myf6 Vitamin D Receptor (VDR)-floxed (Vdr ) mice with mature muscle fibre-specific vitamin D receptor knockout, injected tamoxifen into 8-week-old mice and analysed various phenotypes at 16 weeks of age.
Grip strength reduction was significantly greater in the deficient group (-1.55 ± 2.47 kg) than in the non-deficient group (-1.13 ± 2.47 kg; P = 0.019). Appendicular skeletal muscle mass reduction did not differ significantly between deficient (-0.05 ± 0.79 kg) and non-deficient (-0.01 ± 0.74 kg) groups (P = 0.423). The incidence of new cases of sarcopenia was significantly higher in the deficient group (15 vs. 5 cases; P = 0.039). Skeletal muscle phenotyping of Vdr mice showed no significant differences in muscle weight, myofibre percentage or myofibre cross-sectional area; however, both forelimb and four-limb muscle strength were significantly lower in Vdr mice (males: forelimb, P = 0.048; four-limb, P = 0.029; females: forelimb, P < 0.001; four-limb, P < 0.001). Expression profiling revealed a significant decrease in expression of sarcoendoplasmic reticulum Ca -ATPase (SERCA) 1 (P = 0.019) and SERCA2a (P = 0.049) genes in the Vdr mice. In contrast, expression of non-muscle SERCA2b and myoregulin genes showed no changes.
Vitamin D deficiency affects muscle strength and may contribute to the onset of sarcopenia. Vitamin D-VDR signalling has minimal influence on the regulation of muscle mass in mature myofibres but has a significant influence on muscle strength.
维生素 D 是骨骼肌肉功能所必需的营养物质,但它与肌肉减少症的关系仍不明确,且维生素 D 活性的机制和靶标尚未阐明。本研究旨在阐明维生素 D 在成熟骨骼肌中的作用及其与肌肉减少症的关系。
这是一项采用流行病学研究设计的研究,共纳入了 1653 名参加了日本国立长寿科学研究所纵向老龄化研究的第五次和第七次研究的社区居民,且所有参与者均完成了背景数据的采集。将参与者分为维生素 D 缺乏组(血清 25-羟维生素 D < 20ng/ml)和非缺乏组(血清 25-羟维生素 D ≥ 20ng/ml);根据背景因素(年龄、性别、身高、体重、合并症、吸烟、饮酒、能量摄入、维生素 D 摄入、步数、活动、季节和肌肉减少症)进行倾向评分匹配。比较 4 年内肌肉力量和质量的变化。基础分析中,我们构建了肌纤维特异性维生素 D 受体敲除 Myf6 维生素 D 受体(VDR)- floxed(Vdr)小鼠,在 8 周龄时向小鼠注射他莫昔芬,并在 16 周龄时分析各种表型。
与非缺乏组相比,维生素 D 缺乏组的握力下降更明显(-1.55±2.47kg 比-1.13±2.47kg;P=0.019)。四肢骨骼肌质量减少在缺乏组(-0.05±0.79kg)和非缺乏组(-0.01±0.74kg)之间无显著差异(P=0.423)。缺乏组新发肌肉减少症的病例明显多于非缺乏组(15 例比 5 例;P=0.039)。Vdr 小鼠的骨骼肌表型分析显示,肌肉重量、肌纤维百分比或肌纤维横截面积无显著差异;但 Vdr 小鼠的前肢和四肢肌肉力量均显著降低(雄性:前肢,P=0.048;四肢,P=0.029;雌性:前肢,P<0.001;四肢,P<0.001)。表达谱分析显示,Vdr 小鼠的肌浆网 Ca2+-ATP 酶(SERCA)1(P=0.019)和 SERCA2a(P=0.049)基因的表达显著降低。相反,非肌肉 SERCA2b 和肌调节蛋白基因的表达没有变化。
维生素 D 缺乏会影响肌肉力量,可能导致肌肉减少症的发生。维生素 D-VDR 信号对成熟肌纤维中肌肉质量的调节作用较小,但对肌肉力量有显著影响。